Ifosfamide

Ifosfamide · IFOSFAMIDE 1 g/1 · Injection, Powder, Lyophilized, For Solution · Intravenous · Fresenius Kabi USA, LLC

NDC 63323-0142-10 · 1 VIAL, SINGLE-DOSE in 1 BOX / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, SINGLE-DOSE · ANDA · View full market →

The short version

Only one company currently supplies this market — there is no backup if it stumbles. It is in shortage right now — FDA lists the reason as “demand increase for the drug”.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built

Data sources

CMS NADAC (pharmacy acquisition, weekly)
CMS Part B ASP quarterly payment limits
CMS Maximum Fair Prices (IRA negotiated, NDC-level)
Medicare Part D Spending by Drug (data.cms.gov, name-matched)
VA FSS / Big4 federal contract prices (va.gov, twice monthly)
ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
California SB-17 WAC filings (list price, per package)

Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Medicare Part B pays (ASP+6%)$27.61per billing unit (1 GM)HCPCS J9208 · Jul 1, 2026
Federal contracts pay (FSS)$27.60per unitFresenius Kabi, LLC · May 15, 2025

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Estimated fill cost

WAC per package, as filed

$58.05

Reported to Texas DSHS · 2026 annual filing · Fresenius Kabi USA

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicare Part B (ASP)

Payment limit per 1 GM

$27.613

HCPCS J9208 · Jul 1, 2026 quarter · typically ASP + 6%

Medicaid spend (2025)

$3,027

28 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

Where it's made

Fresenius Kabi USA, LLCUnited States
analysis · manufacture

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

Part D specialty tier
Costs ≥ $950/fill
Biologic (BLA)
Injectable / infused
Orphan-drug exclusivity
REMS program

Regulatory

Application: ANDA076078
TE code: AP
Approval date: May 28, 2002
Patents / exclusivity: None on file

Shortage history

In shortage now — Ifosfamide, Injection, 1 g (NDC 63323-142-10)Jun 12, 2026
Demand increase for the drug
month 3 of a typical 20 for injectable shortages · model puts 21% odds it resolves within 6 months

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Ifosfamide (Injection, Powder, Lyophilized, For Solution)

Labeler	Strength	First seen	Last seen
Fresenius Kabi USA, LLC	IFOSFAMIDE 1 g/1	Jul 15, 2026	Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Ifosfamide — NDC 63323-0142-10," retrieved September 3, 2026, https://drugdashboards.com/drug/63323014210.

Free to cite with attribution — see how the data is put together.